Display options
Cite
Okada DR, Johnson G, Okada RD. Myocardial clearance of technetium-99m-teboroxime in reperfused injured canine myocardium. EJNMMI Res. 2014;4:42doi: 10.1186/s13550-014-0042-6.
Okada, D. R., Johnson, G., & Okada, R. D. (2014). Myocardial clearance of technetium-99m-teboroxime in reperfused injured canine myocardium. EJNMMI research, 442. https://doi.org/10.1186/s13550-014-0042-6
Okada, David R, et al. "Myocardial clearance of technetium-99m-teboroxime in reperfused injured canine myocardium." EJNMMI research vol. 4 (2014): 42. doi: https://doi.org/10.1186/s13550-014-0042-6
Okada DR, Johnson G, Okada RD. Myocardial clearance of technetium-99m-teboroxime in reperfused injured canine myocardium. EJNMMI Res. 2014 Aug 01;4:42. doi: 10.1186/s13550-014-0042-6. eCollection 2014. PMID: 25411652; PMCID: PMC4233307.
Copy Download .nbib Format: NLM
Share it on

EJNMMI Res. 2014 Aug 01;4:42. doi: 10.1186/s13550-014-0042-6. eCollection 2014.

Myocardial clearance of technetium-99m-teboroxime in reperfused injured canine myocardium.

EJNMMI research

David R Okada, Gerald Johnson, Robert D Okada

Affiliations

  1. Brigham and Women's Hospital, Harvard Medical School, Boston 02446, MA, USA.
  2. University of Tulsa, Tulsa 74104, OK, USA ; University of Oklahoma Health Sciences Center, 6208 S. Oswego Ave, Tulsa 74136, OK, USA.

PMID: 25411652 PMCID: PMC4233307 DOI: 10.1186/s13550-014-0042-6

Abstract

BACKGROUND: Recent technical developments using solid-state technology have enabled rapid image acquisition with single photon emission computed tomography (SPECT) and have led to a renewed interest in technetium-99m-teboroxime (Tc-99m-teboroxime) as a myocardial imaging agent. Tc-99m-teboroxime has demonstrated high myocardial extraction, linear myocardial uptake relative to flow even at high flow rates, rapid uptake and clearance kinetics, and differential clearance in the setting of ischemia. However, the myocardial clearance kinetics of Tc-99m-teboroxime in a model of myocardial injury has not been previously reported. Thus, the purposes of this study were to use a canine model of ischemia-reperfusion to (1) compare Tc-99m-teboroxime clearance kinetics in normal and ischemic-reperfused myocardium and (2) assess the utility of Tc-99m-teboroxime clearance kinetics in determining the severity of injury following ischemia-reperfusion.

METHODS: Thirteen dogs underwent left circumflex coronary artery (LCx) occlusion for either 30 min (IR30, n = 6) or 120 min (IR120, n = 7), followed by reperfusion, and finally Tc-99m-teboroxime administration 120 min after reperfusion. Microsphere blood flows were determined at baseline, during occlusion, after reperfusion, and before euthanasia. Post-mortem, area at risk was determined using Evans blue dye, and viability was determined using triphenytetrazolium chloride (TTC) staining. The hearts were then subdivided into 24 pieces and Tc-99m activity was measured in a well counter.

RESULTS: TTC-determined infarct area as a percentage of total left ventricular myocardium was 1.1% ± 0.3% for the IR30 group and 7.5% ± 2.9% for the IR120 group (p < 0.05). During coronary occlusion, both the IR30 and IR120 groups demonstrated decreases in percent wall thickening in the ischemia-reperfusion zone (IRZ) as compared with the normal zone (NZ). In the IR30 group, percent wall thickening in the IRZ recovered during the reperfusion phase as compared with the NZ. In the IR120 group, percent wall thickening in the IRZ remained depressed during the reperfusion phase and through the end of the experiment as compared with the NZ. Final Tc-99m-teboroxime myocardial IRZ/NZ activity ratio was 0.94 ± 0.01 for the IR30 group, compared to 0.80 ± 0.01 for the IR120 group (p < 0.05).

CONCLUSIONS: Tc-99m-teboroxime demonstrates moderate differential clearance in a model of severe injury with 120 min of ischemia-reperfusion, but only minimal differential clearance in a model of mild injury with 30 min of ischemia-reperfusion. Thus, Tc-99m-teboroxime clearance kinetics may be helpful in differentiating normal and minimally injured from severely injured myocardium.

Keywords: Ischemia; Reperfusion; SPECT; Teboroxime

References

  1. J Nucl Med. 1993 Apr;34(4):630-6 - PubMed
  2. Eur J Nucl Med. 1994 Jan;21(1):27-36 - PubMed
  3. Int J Card Imaging. 1992;8(4):277-87 - PubMed
  4. J Nucl Med. 1993 Sep;34(9):1485-93 - PubMed
  5. J Nucl Med. 1989 Nov;30(11):1830-7 - PubMed
  6. J Nucl Med. 1990 Jul;31(7):1183-90 - PubMed
  7. J Nucl Med. 1995 Jun;36(6):1062-8 - PubMed
  8. J Nucl Cardiol. 1996 Jan-Feb;3(1):2-8 - PubMed
  9. J Nucl Cardiol. 2010 Oct;17 (5):890-6 - PubMed
  10. Am J Cardiol. 1990 Oct 16;66(13):9E-15E - PubMed
  11. Eur J Nucl Med. 1989;15(4):180-2 - PubMed
  12. J Nucl Med. 1995 Jan;36(1):111-9 - PubMed
  13. J Am Coll Cardiol. 1990 Nov;16(6):855-61 - PubMed
  14. J Nucl Cardiol. 1994 Mar-Apr;1(2 Pt 1):189-97 - PubMed
  15. J Nucl Cardiol. 1994 May-Jun;1(3):270-9 - PubMed
  16. J Nucl Med. 1993 Feb;34(2):255-9 - PubMed
  17. Am J Cardiol. 1993 Apr 1;71(10 ):848-52 - PubMed
  18. J Nucl Cardiol. 2006 May-Jun;13(3):354-61 - PubMed
  19. Circulation. 1990 Oct;82(4):1402-12 - PubMed
  20. J Nucl Med. 1991 Oct;32(10 ):2000-8 - PubMed
  21. J Nucl Med. 1997 Jan;38(1):138-43 - PubMed
  22. J Nucl Med. 1991 Oct;32(10 ):1979-88 - PubMed
  23. J Nucl Med. 1990 Jan;31(1):67-74 - PubMed
  24. J Nucl Med. 1994 Sep;35(9):1514-9 - PubMed
  25. Am J Cardiol. 1993 Sep 15;72 (9):728-34 - PubMed
  26. J Am Coll Cardiol. 1992 Sep;20(3):712-9 - PubMed
  27. Cardiol Clin. 1994 May;12 (2):169-85 - PubMed
  28. J Nucl Med. 1997 Feb;38(2):274-9 - PubMed
  29. Curr Opin Cardiol. 1991 Dec;6(6):953-64 - PubMed
  30. J Nucl Cardiol. 1996 Jan-Feb;3(1):42-54 - PubMed
  31. Nucl Med Biol. 1993 May;20(4):395-400 - PubMed
  32. J Nucl Cardiol. 1994 Jul-Aug;1(4):338-50 - PubMed

Publication Types